Little is known about the factors associated with frequency of emergency department visits (FEDV) in chronic obstructive pulmonary disease (COPD) patients with recurrent exacerbations.
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) affects more than 10 million people and is the fourth leading cause of death in the United States. 1 It continues to cause a tremendous health and economic burden, with estimated annual costs in the United States of $24 billion in 2000. 2 COPD exacerbations contribute to a significant proportion of this burden, resulting in approximately 1.5 million emergency department (ED) visits per year. 1 It has been suggested that frequent COPD exacerbations are key drivers of hospital and other unscheduled care costs. 3, 4 Many COPD patients repeatedly return to hospital EDs for urgent COPD care, leading to rising health care expenditures. Evidence suggests that patients with frequent COPD exacerbations have a poorer quality of life, 5 a faster decline in lung function, 6 and increased mortality. 7 Although exacerbation frequency is now recognized as an importance factor for morbidity and mortality in COPD, to our knowledge, no studies to date have examined the determinants of the frequency of emergency department visits (FEDV) for COPD exacerbation. Most studies focused on the factors associated with hospitalization for COPD exacerbation, [8] [9] [10] but did not directly address this important topic. Understanding the determinants of FEDV may help identify interventions that reduce the high costs by frequent ED visits and subsequent morbidity and mortality in the patient population. The primary purpose of this prospective multicenter study was to characterize the use of ED services in patients with COPD exacerbation and identify factors associated with FEDV in this patient population.
METHODS

Study Population
This observational study combined data from two identical prospective cohort studies performed in 2000-2001 as part of the Multicenter Airway Research Collaboration, a division of the Emergency Medicine Network (EMNet, www.emnet-usa. org) . Details of the study design and data collection have been previously published. 11 In brief, using a standard protocol, investigators at 29 EDs in 15 U.S. states and 3 Canadian provinces provided 24-hours-a-day coverage for a median of 2 weeks. Repeat visits by individual subjects were excluded. All patients were managed at the discretion of the treating physician. Inclusion criteria were physician diagnosis of COPD; presenting to the ED for treatment of COPD exacerbation, as defined by increasing shortness of breath, worsening cough, or change in sputum production; 12, 13 age ≥55 years;
and the ability to give informed consent. The institutional review boards at each of the 29 participating hospitals approved the study, and informed consent was obtained for all participants.
Data Collection and Processing
Trained research personnel performed the ED interview and assessed patients' baseline clinical characteristics, COPD history, and details of their current COPD exacerbation. Data on ED management and disposition were obtained from chart review. Site investigators reviewed all forms before submission to the EMNet Coordinating Center in Boston, where they underwent further review by trained personnel and then double data entry.
Information on Outcome and Covariates
Each patient's diagnostic group was based on the following question: "Has a doctor ever said that you have asthma, COPD, or chronic bronchitis?" Patients were assigned to the COPD group if they reported COPD, emphysema, or chronic bronchitis. Patients reporting asthma and fulfilling the definition of COPD were classified as having both COPD and asthma (i.e., mixed disease). To address possible diagnostic misclassification, we performed a validation study in a subset of study population using information from spirometry, chest radiograph, and chest computed tomography scan, and 82% of selfreported cases of COPD were confirmed.
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The primary outcome of this study, number of ED visits, was based on the following question: "Over the past 12 months, how many times have you gone to a hospital ED because of your COPD?" The current visit was not counted. Median family income was estimated using home ZIP codes. 15 17, 18 Manual stepwise, multivariate negative binomial regression modeling was performed to assess factors associated with FEDV. Variables associated with FEDV at P<.10 in univariate analyses were considered eligible for inclusion in the multivariate analysis. Age, sex, race, education, and insurance status were included throughout the model building process because of their potential clinical significance. If deletion of a particular variable from the model changed any rate ratios in the existing model by less than 10%, this variable was deleted because it did not show a strong confounding effect on existing variables. 19 We tested for two-way interaction by multiplying the two factors of interest and including an interaction term in the final multivariate model. Likelihood ratio tests were used to examine interactions with the comparison of nested models with and without the interaction variable. Incidence rate ratios (IRRs) are presented with 95% confidence intervals (CI).
We also calculated the population attributable risk (PAR) conferred by PCP status to estimate the percentage of ED visits in our cohort that, theoretically, would not have occurred if all COPD patients had a PCP, assuming a causal relationship between PCP and FEDV. 20 This was calculated on the basis of
, where p is the prevalence of the population who lacked a PCP and IRR is the multivariate-adjusted IRR for lack of PCP. All analyses were performed using Stata version 9.0 software (StataCorp, College Station, Tex, USA). All P values are two-sided, with P<.05 considered statistically significant. We performed two sensitivity analyses. First, to assess the impact of influential observations, we refitted the model by excluding two patients reporting more than 30 ED visits to see how the estimates changed in the final multivariate model. Second, to separate the potentially differential impact of insurance status on FEDV among Canadian patients (n=63), we also refitted the model by excluding Canadian patients.
RESULTS
Of 853 eligible patients, 579 (65%) were enrolled with an exacerbation of asthma or COPD; analysis was restricted to the 397 patients with physician-diagnosed COPD (mixed asthma-COPD or COPD only). Enrolled and nonenrolled patients were similar across several sociodemographic factors (data not shown) except age. Nonenrolled patients were slightly older than enrolled patients (73 vs 70 years, P<.001). For the purpose of this analysis, we excluded 9 patients who had missing data on number of ED visits, leaving 388 patients for the current analysis.
The median age of these ED patients was 69 years and 52% were women (Table 1) . Most participants were white and reported having a PCP and health insurance. About half reported using the ED as their usual site for problem COPD care, and 15% reported using the ED as their usual site for COPD prescriptions. More than 90% of patients reported a history of smoking, with an average of 51.5 pack-years among past and current smokers. Forty-four percent of patients reported having mixed COPD and asthma. Approximately two thirds of patients had been hospitalized for COPD and had taken corticosteroid for COPD; 14% of patients had been intubated for COPD. The use of multiple COPD medications also indicated the disease burden and severity in these elderly patients. Notably, comorbidities of cardiovascular diseases and depression were commonly seen in this population.
Over the past year, this cohort utilized a total of 1,090 ED visits because of COPD exacerbation. The median number of ED visits per person during the past year was 1 (IQR 0-3). Figure 1 shows the number of patients and the number of ED visits during the prior year, by the 4 frequency groups. One hundred thirty-eight patients (36%) reported no prior ED visits, 122 patients (31%) had 1 to 2 visits, 77 patients (20%) had 3 to 5 visits, and 51 patients (13%) had 6 or more visits in the past year. Relatively few frequent ED users were responsible for a disproportionately large number of the total ED visits. Patients with 1 to 2 visits during the past 12 months accounted for 17% of all ED visits; patients with 3 to 5 visits accounted for 27% of total visits; and patients with 6 or more visits accounted for 57% of total visits.
Univariate analysis of factors associated with FEDV for COPD is shown in Table 1 . Nonwhite race, uninsured patients, patients with Medicaid, and mixed disease patients were associated with an increased FEDV during the past year. Patients with an increased FEDV were less likely to be older, have a PCP, and were less likely to have completed high school education and have higher median household income. Sex was unrelated to FEDV. Patients with an increased FEDV were more likely to report a history of systemic steroid use, hospitalization for COPD, intubation for COPD, recent use of inhaled β-agonists and methylxanthine, and depression.
Multivariate analysis showed that Hispanic patients had two times increased incidence rate of ED visits in the past year compared with whites (Table 2 ). Several markers of COPD severity (e.g., history of hospitalization, intubation for COPD, and use of systemic corticosteroids and methylxanthine) were all independently associated with an increased FEDV. In the final multivariate model, having a PCP was the only factor for decreased FEDV. There were no significant two-way interactions in the final model. In our cohort, 90% of patients reported having a PCP. Based on the formula, we estimated that approximately 100 ED visits (i.e., 10%) could have been prevented if all patients in our cohort had a PCP.
We repeated the multivariate model after excluding two patients reporting more than 30 visits, and the results slightly changed. History of intubation was no longer predictive of FEDV (IRR 1.30, 95% CI 0.90-1.87), whereas patients with Medicaid (IRR 1.61, 95% CI 1.03-2.53) and uninsured patients (IRR 2.03, 95% became significantly associated with an increased FEDV compared with those with private insurance. The estimates of other predictors did not materially change. Excluding Canadian patients did not materially change the estimates of insurance status and the other variables in the final model (data not shown).
DISCUSSION
This large, prospective multicenter study is the first to examine factors associated with FEDV among COPD patients presenting to North American EDs for COPD exacerbation. Our results suggest that both disease and health care-related factors are associated with FEDV in this patient population. We believe that our findings may provide evidence as a basis for future development of efficacious interventions to reduce the substantial burden from frequent ED use for COPD care.
It is biologically plausible that patients with more severe COPD will require more ED visits compared to patients with mild disease. Evidence suggests that patients with severe COPD (Global Initiative for Chronic Obstructive Lung Disease
[GOLD] stage 3) had an annual exacerbation frequency of 3.43 compared with 2.68 in those with moderate COPD (GOLD stage 2). 21 Consistent with this finding, we further identified that frequent ED users are more likely to have several markers of severe COPD, including previous hospitalizations, prior intubations, and past use of systemic corticosteroids and methylxanthine. Similar to our findings, in a prospective study of asthma, previous hospitalization was the strongest predictor for frequent ED visits.
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To better understand other factors associated with FEDV in our study, it is important to distinguish recurrence of COPD exacerbation from relapse. The major difference is that the former refers to recurrent events over the course of a longer period of time, such as 1 year in our study. In contrast, relapse refers to revisit to the ED for the same exacerbation (usually within 2 to 4 weeks of the index ED visit). As a result, the predictors of relapse are not necessarily the predictors of FEDV in a longer period. Conceptually, relapse is more likely to be related to acute/medical factors, such as severity exacerbation (e.g., respiratory rate). 23 By contrast, recurrent ED visits has a broader meaning, and therefore it may be connected to health care-related factors in addition to disease factors. A number of studies have identified a set of social and health care-related predictors of FEDV across diseases, such as homelessness, poverty, socioeconomic distress, and government-supported insurance. [24] [25] [26] [27] In this study, we found two health care-related factors, insurance status (after excluding outliers) and lack of a PCP, that were associated with frequent ED use. Indeed, a high rate of ED visits may suggest that a population lacks access to preventive and routine care provided by PCP. As a result, when care is needed, patients sometimes resort to using the ED. This finding is consistent with a recent study that demonstrates an inverse association between primary care densities and ED visit densities in the United States. 28 Our study further estimated that 1 in 10 ED Chronic obstructive pulmonary disease (COPD) Figure 1 . Number of patients and number of emergency department (ED) visits made by individuals according to 4 frequency levels of ED use during the past year. For example, on the far right side, 51 patients had 6 or more visits in the past year, accounting for a total of 620 ED visits.
visits could have been prevented if PCP is available for all patients. Therefore, primary care system may play a critical role in solving frequent ED utilization for COPD exacerbation. Lack of a PCP is largely because of lack of health insurance. 29 Therefore, uninsured COPD patients are also at greater risk of an increased FEDV in our study, compared to patients with any type of health insurance. This finding is consistent with the national trend that the continued increase in the number of uninsured parallels with the increase in the ED visits. [30] [31] [32] [33] In observational studies, an alternative explanation for the association between insurance and ED visits is confounding by indication. That is, patients who have insurance are more likely to be healthy than patient who do not have health insurance, and therefore they appeared to be less likely to visit the ED for COPD exacerbation. Despite the enormous burden from ED visits, the recommendations regarding how to reduce ED visits in current COPD guidelines are still lacking. 12, 13 This is partly because of the lack of evidence. Many pharmacologic interventions have been associated with reductions in exacerbation; however, the drug effectiveness on decrease in ED visits remains unclear.
More recent studies suggest that the improvement in exacerbation rate can be translated into reduced hospitalization rate, 34, 35 but no significant difference in ED visits. 34 Another possible approach to reduce future ED visits is to provide PCP follow-up in COPD patients who are discharged from the ED. In a prospective study among patients who have been recently treated in the ED for COPD or asthma, follow-up office visits were associated with a significant reduction in the 90-day risk of an ED visit. 36 Provision of post-ED PCP follow-up may fill in the gap between ED and primary care in the continuum of COPD care. In asthma, the current standard of practice for exacerbations includes a follow-up medical appointment within 3 to 5 days after ED visit. 37 We believe that provision of PCP follow-up after ED visit may serve as a possible solution to reduce the burden of frequent ED visits in COPD patients. There are relatively sparse data on racial/ethnic disparities in COPD. To our knowledge, this is the first study demonstrating racial/ethnic differences in ED utilization for COPD exacerbation. Similar to our findings, Boudreaux et al. 38 have
shown that black and Hispanic asthma patients were more likely to utilize the ED and concluded race/ethnicity-based deficiencies exist in asthma. In our study, after controlling for potential confounders such as educational level and insurance status, Hispanic patients remain more likely to utilize the ED, with a reduced IRR from 3.50 in univariate analysis to 1.97 in multivariate analysis. The persisting race/ethnicity differences in ED utilization can be explained by geographic access, transportation, primary language, health beliefs, patient perceptions of need, or patient-provider communication. 39 The pathways through which racial/ethnicity affect health care utilization are complex. Further investigations are needed to better understand the underlying reasons for racial/ethnic differences in ED utilization in patients with COPD exacerbation. Our results must be interpreted in the context of the study design. First, history of prior ED use was self-reported and there was no attempt to verify the accuracy of the stated information. However, as shown in the sensitivity analysis, our findings did not substantially change after excluding influential observations with high numbers of ED visits. Second, this study examined only patients who presented to the ED with an acute exacerbation, and thus it may not be generalizable to all stable, population-based COPD patients. However, because our goal is to characterize the frequent visitors to the ED, the findings are directly relevant to our objectives. Finally, because of the small sample size of Hispanic patients (n=27, 7%), the racial/ethnic differences in ED utilization need to be replicated in future studies.
In summary, 13% of COPD patients had 6 or more ED visits in our cohort, accounting for 57% of the total ED visits for COPD exacerbation. Our results suggest that both disease and health care-related factors were associated with FEDV. Patients with markers of more severe COPD were associated with an increased FEDV, whereas patients who had a PCP were associated with a decreased FEDV. Multidisciplinary efforts through PCP follow-up should be assessed to test the effects on reducing the high morbidity and cost of recurrent COPD exacerbations. Hispanic patients were more likely to utilize the ED in our study. Further investigations are needed to better understand the underlying reasons for racial/ethnic differences in ED utilization in patients with COPD exacerbation.
